Fat malabsorption in cystic fibrosis: comparison of quantitative fat assay and a novel assay using fecal lauric/behenic acid
- PMID: 20179641
- PMCID: PMC2847657
- DOI: 10.1097/MPG.0b013e3181b18308
Fat malabsorption in cystic fibrosis: comparison of quantitative fat assay and a novel assay using fecal lauric/behenic acid
Abstract
Objectives: The gold standard for the diagnosis of fat malabsorption, the 72-hour fat balance study, requires a 3-day collection to generate a coefficient of fat absorption (CFA). We hypothesized that a new test using behenic acid (behenate test) as a nonabsorbable lipid marker may provide a facile means to assess fat absorption. The study proposed to answer 2 questions: first, whether the behenate test correlated with the gold standard and, second, whether the CFA improved when taking pancreatic enzymes during meals instead of taking them before meals.
Patients and methods: The study compared the behenate test with the gold standard in 15 patients with cystic fibrosis during 3 arms that require 3- to 4-day hospitalization: first, taking pancreatic enzymes before meals; second, taking it during meals; and third, without taking it.
Results: The mean CFA was 78.3% when pancreatic enzymes were taken during meals and 80.4% when these enzymes were taken before meals. Correlation between the CFA and the behenate test for collections during all 3 arms was r = 0.219 (P = 0.001).
Conclusions: Timing of ingestion of pancreatic enzymes does not significantly alter the CFA. Although the CFA correlates with the behenate test, the correlation is not robust enough to justify replacement of the gold standard by this test. It is unclear whether the poor correlation between tests relates to intermeal variability in fat excretion or other factors; however, the behenate test may be suitable as a screening test for the detection of fat malabsorption.
Figures




Similar articles
-
Fat malabsorption in cystic fibrosis patients receiving enzyme replacement therapy is due to impaired intestinal uptake of long-chain fatty acids.Am J Clin Nutr. 1999 Jan;69(1):127-34. doi: 10.1093/ajcn/69.1.127. Am J Clin Nutr. 1999. PMID: 9925134 Clinical Trial.
-
Improved residual fat malabsorption and growth in children with cystic fibrosis treated with a novel oral structured lipid supplement: A randomized controlled trial.PLoS One. 2020 May 8;15(5):e0232685. doi: 10.1371/journal.pone.0232685. eCollection 2020. PLoS One. 2020. PMID: 32384122 Free PMC article. Clinical Trial.
-
Evaluation of the 13C-triolein breath test for fat malabsorption in adult patients with cystic fibrosis.J Gastroenterol Hepatol. 2004 Apr;19(4):448-53. doi: 10.1111/j.1440-1746.2003.03310.x. J Gastroenterol Hepatol. 2004. PMID: 15012784 Clinical Trial.
-
Diagnosis and treatment of intestinal malabsorption in cystic fibrosis.Pediatr Pulmonol. 2006 Jan;41(1):35-49. doi: 10.1002/ppul.20286. Pediatr Pulmonol. 2006. PMID: 16288483 Review.
-
Enzyme therapy for malabsorption in exocrine pancreatic insufficiency.Pancreas. 1989;4(4):496-503. doi: 10.1097/00006676-198908000-00016. Pancreas. 1989. PMID: 2668933 Review.
Cited by
-
Impaired intestinal free fatty acid transport followed by chylomicron malformation, not pancreatic insufficiency, cause metabolic defects in cystic fibrosis.J Lipid Res. 2024 Jul;65(7):100551. doi: 10.1016/j.jlr.2024.100551. Epub 2024 Jul 13. J Lipid Res. 2024. PMID: 39002195 Free PMC article.
-
Cystic fibrosis-related oxidative stress and intestinal lipid disorders.Antioxid Redox Signal. 2015 Mar 1;22(7):614-31. doi: 10.1089/ars.2014.6012. Epub 2015 Jan 22. Antioxid Redox Signal. 2015. PMID: 25611180 Free PMC article. Review.
-
Pancreatic exocrine insufficiency: Comparing fecal elastase 1 with 72-h stool for fecal fat estimation.Indian J Gastroenterol. 2016 Nov;35(6):441-444. doi: 10.1007/s12664-016-0714-4. Epub 2016 Nov 23. Indian J Gastroenterol. 2016. PMID: 27878466
-
Association between faecal pH and fat absorption in children with cystic fibrosis on a controlled diet and enzyme supplements dose.Pediatr Res. 2021 Jan;89(1):205-210. doi: 10.1038/s41390-020-0860-3. Epub 2020 Apr 4. Pediatr Res. 2021. PMID: 32247283
-
Clinical validation of an evidence-based method to adjust Pancreatic Enzyme Replacement Therapy through a prospective interventional study in paediatric patients with Cystic Fibrosis.PLoS One. 2019 Mar 12;14(3):e0213216. doi: 10.1371/journal.pone.0213216. eCollection 2019. PLoS One. 2019. PMID: 30861039 Free PMC article.
References
-
- Schmitz J. Maldigestion and Malabsorption. In: Walker WA, et al., editors. Pediatric Gastrointestinal Disease. New York: Mosby; 2000. pp. 48–55.
-
- Van de Kamer JH, Huinink H, Weyers HA. Rapid method for the determination of fat in feces. J Biol Chem. 1949;177:349–355. - PubMed
-
- Jandacek RJ, Heubi JE, Tso P. A novel and non-invasive method of measuring intestinal fat absorption. Gastroenterology. 2004;127:139–144. - PubMed
-
- Metcalfe LD, Schmitz AA, Pelka JR. Rapid preparation of Fatty Acid Esters from Lipids for Gas Chromatographic Analysis. Anal Chem. 1966;38:514–515.
-
- Schneider MU, Demling L, Jones SA, et al. NMR spectrometry. A new method for total stool fat quantification in chronic pancreatitis. Dig Dis Sciences. 1987;32:494–499. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical